Card-brand restrictions on peptide merchants are creating serious consequences throughout the payments industry. Learn how potential six-figure fines against acquiring banks and processors can lead to frozen funds, sudden account closures, and fewer processing options for peptide businesses.

Mastercard has added transaction and volume fees for businesses classified as specialty merchants. In 2ndAP’s view, this is a pure money grab: the published guidance identifies new charges, but no new merchant-facing fraud-prevention service or measurable protection purchased by those fees.

Mastercard is moving toward faster investigations and broader measurement of merchant risk. Here is what card-not-present and high-risk businesses should know about the new 72-hour standard, GMAP, and protecting their processing relationship.

2nd Amendment Processing has partnered with Biller Genie to help businesses automate accounts receivable, streamline invoicing and collections, integrate payments with accounting software, and get paid faster.

The FDA's July 2026 review of seven peptides could have far-reaching implications beyond healthcare. As regulators evaluate potential changes to compounding eligibility, payment processors, banks, and merchants are watching closely. Learn how increased regulatory clarity may affect merchant account approvals, underwriting standards, banking relationships, and payment processing opportunities for businesses operating in the peptide industry.